Reviva Pharmaceuticals

Yahoo Finance • 4 days ago

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in t... Full story

Yahoo Finance • 9 days ago

After-Hours Movers: Biotech And Medtech Stocks Jump On Volume And News

(RTTNews) - A wave of after-hours activity swept through select biotech and medical device names Thursday, with several micro- and mid-cap stocks posting sharp gains following session-end catalysts, volume spikes, or pipeline updates. Belo... Full story

Yahoo Finance • 11 days ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 23 days ago

Reviva Pharmaceuticals announces pricing of $9M public offering

* Reviva Pharmaceuticals (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]) announced [https://seekingalpha.com/pr/20238101-reviva-pharmaceuticals-holdings-inc-announces-pricing-of-9-million-public-offering] on Thursday a public offeri... Full story

Yahoo Finance • 23 days ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in... Full story

Yahoo Finance • 23 days ago

Reviva Pharmaceuticals announces proposed public offering

* Reviva Pharmaceuticals Holdings (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]) on Thursday said it intends to offer shares of its common stock and warrants to purchase shares of common stock in a public offering. * All of the s... Full story

Yahoo Finance • 23 days ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in... Full story

Yahoo Finance • 2 months ago

Reviva Narrows Loss 23% in Fiscal Q2

Key Points Net loss (GAAP) narrowed to $6.1 million in Q2 2025, a 22.8% improvement from the prior-year period, driven by reduced research and development spending. No product revenue reported; The company’s clinical-stage focus and cash... Full story

Yahoo Finance • 2 months ago

Reviva Pharmaceuticals GAAP EPS of -$0.12 in-line

* Reviva Pharmaceuticals press release [https://seekingalpha.com/pr/20202002-reviva-reports-second-quarter-2025-financial-results-and-recent-business-highlights] (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]): Q2 GAAP EPS of -$0.12... Full story

Yahoo Finance • 2 months ago

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized do... Full story

Yahoo Finance • 4 months ago

Reviva Pharmaceuticals holdings announces pricing of $10M public offering

* Reviva Pharmaceuticals Holdings (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]) on Thursday announced the pricing of its public offering with existing and new healthcare focused institutional investors. * The offering entails th... Full story

Yahoo Finance • 4 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in t... Full story

Yahoo Finance • 4 months ago

Reviva Pharmaceuticals stock falls after announcing public offering

Investing.com -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) stock tumbled 23.4% after the late-stage pharmaceutical company announced its intention to offer shares of common stock and warrants in a public offering. The company, w... Full story

Yahoo Finance • 4 months ago

Reviva Pharmaceuticals announces public offering of common stock

CUPERTINO, Calif. - Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH), a pharmaceutical company with a market capitalization of $35.6 million, announced today its intention to offer shares of common stock and warrants in a public offerin... Full story

Yahoo Finance • 4 months ago

Reviva Pharmaceuticals announces public offering; shares down nearly 15%

* Reviva Pharmaceuticals (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]) plans to offer common stock or equivalents and warrants in a public offering. * All securities in the offering will be sold by the company. * Proceeds will... Full story

Yahoo Finance • 4 months ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in t... Full story

Yahoo Finance • 4 months ago

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinfl... Full story

Yahoo Finance • 5 months ago

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

– 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment – – Full data set from RECOVER OLE highlighting clinical response, safety, e... Full story

Yahoo Finance • 6 months ago

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

– Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-20... Full story

Yahoo Finance • 6 months ago

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous... Full story